EHA 2022 | Advances in MDS treatment: the promise of magrolimab plus azacitidine
In this video, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, briefly highlights the promise of novel combinations for the treatment of myelodysplastic syndromes (MDS), drawing focus on the safety and efficacy of magrolimab combined with azacitidine and the promise of this combination for the future treatment of MDS. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis.
